Study summary
A monthly or every-2-month injection prevented most swelling attacks
81%fewer attacks with 4-weekly dosing
What was tested
Donidalorsen, an antisense drug that lowers prekallikrein production, given every 4 or 8 weeks, against placebo, to prevent attacks.
What they found
- Attack rate was 81% lower with 4-weekly dosing and 55% lower with 8-weekly dosing.
- Quality of life improved substantially.
What it means
Adds a less frequent injection to the prevention options.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.